Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents

被引：0
|
作者：
Naiker, P.
Makan, H. A.
Omar, M. A. K.
Kedijang, T.
Kong, L. L. L.
机构：
[1] St Augustines Hosp, Durban, South Africa
[2] Novo Nordisk, Johannesburg, South Africa
[3] Novo Nordisk, Singapore, Singapore
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0983
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [41] Improved Safety and Efficacy Profile in Patients with Type 2 Diabetes Treated with Biphasic Insulin Aspart 30 (BIAsp 30): Iran Subgroup of the IMPROVE Study
    Esteghamati, Alireza
    Rajabian, Reza
    Amini, Masoud
    Bahrami, Amir
    Khamseh, Mohammad Ebrahim
    Ardekani, Mohammad Afkhami
    Rizi, Ehsan Parvaresh
    DIABETES, 2009, 58 : A527 - A527
  • [42] Long-term evaluation of the cost-effectiveness of biphasic insulin aspart 30 versus insulin glargine in poorly controlled patients with type 2 diabetes receiving oral antidiabetic agents
    Cobden, D
    Palmer, A
    Nicklasson, L
    Roze, S
    Garber, A
    DIABETOLOGIA, 2005, 48 : A336 - A336
  • [43] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    DIABETES, 2018, 67
  • [44] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
    Thorisdottir, Rannveig L.
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens S.
    DIABETES, 2007, 56 : A555 - A555
  • [45] In inadequately controlled patients with type 2 diabetes, Biphasic Insulin Asparti 30 combined with Pioglitazone provides better glycemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulfonylurea combination
    Raz, I
    Stranks, S
    Filipczak, R
    Joshi, P
    Lertoft, B
    Råstam, J
    Chow, F
    DIABETES, 2003, 52 : A453 - A454
  • [46] Biphasic insulin aspart 30 combined with metformin provides better glycemic control in poorly controlled type 2 diabetic patients
    Kvapil, M
    Mikolajczyk-Swatko, A
    Ostergaard, AH
    Shestakova, M
    DIABETES, 2002, 51 : A104 - A105
  • [47] Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US
    Ray, J. A.
    Valentine, W. J.
    Roze, S.
    Nicklasson, L.
    Cobden, D.
    Raskin, P.
    Garber, A.
    Palmer, A. J.
    DIABETES OBESITY & METABOLISM, 2007, 9 (01): : 103 - 113
  • [48] 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
    Andreas Liebl
    Viswanathan Mohan
    Wenying Yang
    Krzysztof Strojek
    Sultan Linjawi
    Drugs in R&D, 2018, 18 : 27 - 39
  • [49] 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
    Liebl, Andreas
    Mohan, Viswanathan
    Yang, Wenying
    Strojek, Krzysztof
    Linjawi, Sultan
    DRUGS IN R&D, 2018, 18 (01) : 27 - 39
  • [50] Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study
    Song, Kee-Ho
    Kim, Jung Min
    Noh, Jung-Hyun
    Park, Yongsoo
    Son, Hyun-Shik
    Min, Kyong Wan
    Ko, Kyung Soo
    DIABETES & METABOLISM JOURNAL, 2013, 37 (02) : 117 - 124
12345